SynAct Pharma has announced top-line results from BEGIN, a phase IIa study of AP1189 in rheumatoid arthritis. The company's CEO Jeppe Øvlesen and CMO
Watch the full interview at biostock.se:
https://www.biostock.se/en/2021/12/biostock-studio-synact-pharma-comments-on-the-promising-study-results-in-ra/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
https://news.cision.com/synact/r/biostock-studio--synact-pharma-comments-on-the-promising-study-results-in-ra,c3465523
(c) 2021 Cision. All rights reserved., source